TLSI Insider Trading Activity and SEC Form 4 Filings
TLSI insider trading summary
Over the past 12 months, insiders at TriSalus Life Sciences, Inc. (TLSI) reported 18 sales worth $140K by 5 insiders and 6 open-market purchases worth $1.8M by 5 insiders on SEC Form 4. Net insider buying was $1.6M.
Latest TLSI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Bryan F. Cox | Chief of Research | Sell | $1K (296 @ $4.39) |
| Oct 5, 2026 | Jennifer Stevens | Chief Regulatory Officer | Sell | $1K (316 @ $4.39) |
| Oct 5, 2026 | Richard Marshak | Chief Commercial Officer | Sell | $1K (325 @ $4.39) |
| May 15, 2026 | Richard Marshak | Chief Commercial Officer | Sell | $1K (543 @ $2.67) |
| Mar 17, 2026 | Mary T Szela | CEO and President | Sell | $61K (15,944 @ $3.85) |
| Mar 16, 2026 | Bryan F. Cox | Chief of Research | Sell | $2K (579 @ $4.12) |
| Mar 16, 2026 | Richard Marshak | Chief Commercial Officer | Sell | $2K (419 @ $4.12) |
| Mar 16, 2026 | Jodi Devlin | Chief of Clinical Operations | Sell | $1K (273 @ $4.12) |
| Mar 16, 2026 | Jennifer Stevens | Chief Regulatory Officer | Sell | $3K (774 @ $4.12) |
| Mar 12, 2026 | Jodi Devlin | Chief of Clinical Operations | Sell | $7K (1,772 @ $4.09) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.